<SEC-DOCUMENT>0001193125-24-219853.txt : 20240917
<SEC-HEADER>0001193125-24-219853.hdr.sgml : 20240917
<ACCEPTANCE-DATETIME>20240916213627
ACCESSION NUMBER:		0001193125-24-219853
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240916
FILED AS OF DATE:		20240917
DATE AS OF CHANGE:		20240916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241302382

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d871529d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as September 16, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Immutep&#146;s Efti in Combination with MSD&#146;s KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="font-size:6.5pt">&reg;</FONT></SUP> Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck
Cancer</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: September 16, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d871529dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g871529dsp001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #70b682">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep&#146;s Efti in Combination with MSD&#146;s KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Leads to Positive
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Efficacy with Favourable Safety in First Line Head and Neck Cancer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In patients with any <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS &#8805;1), efti in combination
with KEYTRUDA outperformance is largest in CPS &#8805;20 with 31.0% ORR (34.5% ORR including partial response after data <FONT STYLE="white-space:nowrap">cut-off)</FONT> versus 18.5% ORR for KEYTRUDA </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti in combination with KEYTRUDA led to a high durability of response of 17.5 months in patients with any <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression and combination continues to have favourable safety profile </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Statistically significant increase in absolute lymphocyte count biomarker seen in the efti in combination with
KEYTRUDA arm shows efti&#146;s biological activity in a randomised setting </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Based on the high unmet need and encouraging results to date, with Overall Survival expected in 2025, the path
forward will be discussed with regulatory agencies </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; September</B><B></B><B>&nbsp;16, 2024 &#150;</B>
<U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune
disease, today announces positive efficacy and safety results from the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA)
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck
squamous cell carcinoma patients (1L HNSCC). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These results with a data <FONT STYLE="white-space:nowrap">cut-off</FONT> of 11&nbsp;March 2024 were
selected as a Proffered Paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 and were presented by Claus Kristensen, M.D., Ph.D., Head of Section for Thoracic and Head and Neck Oncology, Rigshospitalet,
Copenhagen, Denmark, on 15 September. The data adds to the previously reported overall response rates and safety data on 27&nbsp;June and 12 July. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Kristensen </B>stated<B>,</B> &#147;The efficacy and safety data in <FONT STYLE="white-space:nowrap">TACTI-003</FONT> are very
encouraging and show the significant potential of this novel immunotherapy combination to fight <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> head and neck squamous cell carcinomas. The clinically
meaningful improvement in responses for patients with high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression in the randomised portion of the trial, combined with the compelling response rates in patients with no <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression, are a testament to the complementary nature of efti in combination with KEYTRUDA. I am particularly impressed that these higher response rates and clear increase in biological activity seen in the
efti arm do not come at the expense of durability of response or lead to an increased toxicity profile, which is often the case when combining therapies in the search for more efficacious treatments for cancer patients.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Fr&eacute;d&eacute;ric Triebel, CSO of Immutep</B>, said &#147;Through multiple clinical trials, we see the promise of efti to not
only improve cancer patients&#146; clinical responses to immune checkpoint inhibitors, but also to expand patient populations who respond to them including patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. Once again,
the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> trial has reinforced efti&#146;s positive impact on both these fronts. We are excited to see efti in combination with KEYTRUDA now driving a <FONT STYLE="white-space:nowrap">1.9-fold</FONT>
increase in responses for head and neck cancer patients with high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression as compared to KEYTRUDA alone, and a statistically significant increase in absolute lymphocyte count in the treatment arm
showing efti&#146;s biological activity in a randomised setting.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g871529dsp001.jpg" ALT="LOGO" STYLE="width:2.17778in;height:0.742361in;">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #70b682">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marc Voigt, CEO of Immutep</B>, added &#147;As we move into the latter half of 2024, we will continue to
follow the data in <FONT STYLE="white-space:nowrap">TACTI-003</FONT> and start to engage with regulatory authorities regarding potential paths forward. We are certainly pleased with durability we are seeing, which is consistent with other trials in
which efti combined with KEYTRUDA achieves a high DOR, unlike many other therapeutic combinations. We are hopeful this positive duration of response continues and, as seen in first line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung
cancer in the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> trial evaluating efti in combination with KEYTRUDA, eventually contributes to an overall survival benefit for patients with first line head and neck cancer.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ESMO Congress 2024 Proffered Paper Oral Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title:<B> </B>Primary Results from <FONT STYLE="white-space:nowrap">TACTI-003:</FONT> A Randomized Phase IIb Trial Comparing Eftilagimod Alpha (soluble <FONT
STYLE="white-space:nowrap">LAG-3)</FONT> Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with CPS &#8805;1 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Highlights from Randomised Cohort A in 1L HNSCC Patients with Any <FONT STYLE="white-space:nowrap">PD-L1</FONT> Expression (CPS
</B>&#8805;<B></B><B>1) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Efti leads to higher Objective Response Rates (ORR) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti in combination with pembrolizumab (E+P) led to a 32.8% ORR (34.5% including one partial response reported
after data <FONT STYLE="white-space:nowrap">cut-off)</FONT> in evaluable patients with CPS &#8805;1 (N=58) compared to 26.7% for pembrolizumab in evaluable patients with CPS &#8805;1 (N=60), according to RECIST 1.1. Imbalances of prognostic markers
towards the pembrolizumab alone arm included HPV status, smoking status, and primary tumour location. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">E+P outperformance in patients with any <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression was strongest in
high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expressing patients (CPS &#8805;20) with a 31.0% ORR (N=29) versus an 18.5% ORR for pembrolizumab alone (N=27), along with a complete response rate of 6.9% in E+P arm versus 3.7% for pembrolizumab
alone. An additional partial response was reported in CPS &#8805;20 after data <FONT STYLE="white-space:nowrap">cut-off</FONT> leading to a 34.5% ORR, a <FONT STYLE="white-space:nowrap">1.9-fold</FONT> increase in responses over pembrolizumab alone
in this patient group. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Efti maintains a high Duration of Response (DOR) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Durability of response was achieved with the addition of efti with a median DOR of 17.5 months in the E+P arm
(N=58) as compared to 17.1 months in the pembrolizumab alone arm (N=60) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Data compares favourably to other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> combinations with cytotoxic drugs like chemotherapy or EGFR inhibitors, including a historical DOR of ~6 to ~7 months from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> combined with chemotherapy in 1L HNSCC<SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="white-space:nowrap">1-4</FONT> </SUP> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Efti increases Biological Activity </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A statistically significant increase in absolute lymphocyte count (ALC), measured as an exploratory biomarker,
was seen in the E+P arm as shown in the graphic below, indicating an effective efti-induced immune response in this randomised setting </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g871529dsp001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #70b682">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ALC increase is in line with data from other Phase II trials evaluating efti in combination with chemotherapy in
metastatic breast cancer or pembrolizumab in <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer<SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="white-space:nowrap">5-6</FONT></SUP> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g871529g0916151421919.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Efti continues to have favourable safety profile </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti in combination with pembrolizumab continues to have a favourable safety profile with no new safety signals
observed </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discontinuation rate from treatment emergent adverse events was similar for both E+P (4.3%) and for pembrolizumab
alone (4.4%) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unlike other combinations with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, E+P continues to have a comparable safety profile to pembrolizumab alone other than injection site reactions as expected with efti&#146;s subcutaneous
delivery </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, E+P drives a high ORR and Disease Control Rate (DCR) in 1L HNSCC patients regardless of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression.<B> </B>In Cohorts A and B together (N=89), E+P achieved a 33.7% ORR (34.8% including one partial response reported after data <FONT STYLE="white-space:nowrap">cut-off)</FONT> including 31 patients
in Cohort B with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> (CPS &lt;1). E+P also achieved a higher DCR compared to pembrolizumab monotherapy across all <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression levels, with a consistent
increase from 58.1% DCR in CPS &lt;1, to 69.0% DCR in CPS <FONT STYLE="white-space:nowrap">1-19,</FONT> to 75.9% DCR in CPS &#8805;20. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This new data adds
to the body of evidence that efti&#146;s activation of antigen-presenting cells provides a strong boost to the immune system, enhancing the potential of immune checkpoint inhibitors (ICI) such as KEYTRUDA. As the only MHC Class&nbsp;II agonist in
clinical development today, efti generates a broad anti-cancer immune response in combination with ICIs regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, including for patients with negative
<FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, in a unique and safe manner across multiple different cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESMO Proferred Paper Oral
Presentation slides are available on the <U>Posters&nbsp;&amp; Publications</U> section of Immutep&#146;s website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Steps </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep will continue to follow the maturing data from <FONT STYLE="white-space:nowrap">TACTI-003,</FONT> with the most relevant endpoint of Overall Survival
expected in 2025, and engage with regulatory authorities regarding potential paths forward. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g871529dsp001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #70b682">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck
Sharp&nbsp;&amp; Dohme LLC, a subsidiary of Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">TACTI-003</FONT>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Two ACTive <FONT STYLE="white-space:nowrap">Immunotherapies-003</FONT> <FONT STYLE="white-space:nowrap">(TACTI-003)</FONT> trial is an ongoing
Phase IIb study (also known as <FONT STYLE="white-space:nowrap">KEYNOTE-C34)</FONT> evaluating eftilagimod alpha (efti), Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist, in
combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
(pembrolizumab) as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The randomized Cohort A portion of the study is evaluating efti in combination with pembrolizumab as compared to pembrolizumab
monotherapy in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive (Combined Positive Score [CPS] &#8805;1) tumours, whereas Cohort B is evaluating efti in combination with pembrolizumab in patients with <FONT
STYLE="white-space:nowrap">PD-L1</FONT> negative tumours (CPS &lt;1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of the study is Objective Response Rate of evaluable patients
according to RECIST 1.1. Secondary endpoints include Overall Survival, Objective Response Rate according to iRECIST, Progression Free Survival, and Duration of Response. For more information about the Phase IIb trial, visit clinicaltrials.gov
(NCT04811027). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte
Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to
leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>catherine.strong@sodali.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cohen EEW et al. Lancet. 2019 Jan <FONT STYLE="white-space:nowrap">12;393(10167):156-167.</FONT> doi: <FONT
STYLE="white-space:nowrap">10.1016/S0140-6736(18)31999-8.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Burtness B et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi:
<FONT STYLE="white-space:nowrap">10.1016/S0140-6736(19)32591-7.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Haddad RI et al. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dzienis M et al. J Clin Oncol. 2024 Jul 22;42:2989-2999. doi: 10.1200/JCO.23.02625. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Wildiers H et al. Clin Cancer Res. 2024 Feb <FONT STYLE="white-space:nowrap">1;30(3):532-541.</FONT> doi: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10.1158/1078-0432.CCR-23-1173.</FONT></FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forster M et al. Journal for ImmunoTherapy of Cancer 2023;11. doi: 10.1136/jitc-2023-SITC2023.0595.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g871529dsp001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g871529dsp001.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M&E;FIJ_R;7^7W'A<:4XPS&A.*2E4PZYGWY9S2_#3[CZ!\;RO/^SW<S2$EY?
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M_P! U:N7)O\ F(_[<_)GC\$?#F/K1_*J._:S_P!5X%_ZZ^(?_1>D49SMA_\
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MH_B*TL$:\M+1[J6PU#29;ORUN;1,2F%XKV=6,:NZ/$@*8)*&P;'Z"?#[X_\
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M3J73O>2U6ST=NB^XX:N2Y96Q+Q=7"J6(<HS<^:=^:%N5V4K:<JZ=#T(@$$$
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9B(H"JBH JJH'0   #VH =0 4 % !0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g871529g0916151421919.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g871529g0916151421919.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y 1D# 2(  A$! Q$!_\0
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MWR_\\1_WW4M% $6^7_GB/^^Z-\O_ #Q'_?=2T4 1;Y?^>(_[[HWR_P#/$?\
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M_,MANDW 9*[L?A[\#\:X>XU+3;'QEJEU?*;JV'[ED^S >4WRY]W^M>D#D<4
M<U+K.I?;BD4/[HR*HS&>/;/OSSVQ6SYDPO9,09^0?Q#U-7*A7_C\D_ZYK_,T
M 9NNRW/]B716T+;5W,H899002/RS21"XOO+N7?S;<OYL A<!60K@!O7J36S6
M#;YT#5!9MQIMVY-NW:&4\F/Z'J/?(]*6SN5&"E=K<TH ]M"D,-F$C0!556&
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M>3[FK%0K_P ?DG_7-?YF@":BBB@ HHHH **** "BBB@ HHHH **** "H+/\
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MH.* '^=%_P ]%_.CSHO^>B_G7G&D:WXHO-;MK"XLDBC>1H&F:V(&Z#/F,?\
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A*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
